# Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

> **NCT04340882** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Non-Small Lung Cell Cancer
- Recurrent Non-Small Lung Cell Cancer
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT04340882
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-05
- **Primary completion:** 2026-09-02
- **Final completion:** 2030-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340882, "Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04340882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*